Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2016

Open Access 01-12-2016 | Research article

An assessment of the impact of herb-drug combinations used by cancer patients

Authors: Saud M. Alsanad, Rachel L. Howard, Elizabeth M. Williamson

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Login to get access

Abstract

Background

Herb/Dietary Supplements (HDS) are the most popular Complementary and Alternative Medicine (CAM) modality used by cancer patients and the only type which involves the ingestion of substances which may interfere with the efficacy and safety of conventional medicines. This study aimed to assess the level of use of HDS in cancer patients undergoing treatment in the UK, and their perceptions of their effects, using 127 case histories of patients who were taking HDS. Previous studies have evaluated the risks of interactions between HDS and conventional drugs on the basis on numbers of patient using HDSs, so our study aimed to further this exploration by examining the actual drug combinations taken by individual patients and their potential safety.

Method

Three hundred seventy-five cancer patients attending oncology departments and centres of palliative care at the Oxford University Hospitals Trust (OUH), Duchess of Kent House, Sobell House, and Nettlebed Hospice participated in a self-administered questionnaire survey about their HDS use with their prescribed medicines. The classification system of Stockley’s Herbal Medicine’s Interactions was adopted to assess the potential risk of herb-drug interactions for these patients.

Results

127/375 (34 %; 95 % CI 29, 39) consumed HDS, amounting to 101 different products. Most combinations were assessed as ‘no interaction’, 22 combinations were categorised as ‘doubt about outcomes of use’, 6 combinations as ‘Potentially hazardous outcome’, one combination as an interaction with ‘Significant hazard’, and one combination as an interaction of “Life-threatening outcome”. Most patients did not report any adverse events.

Conclusion

Most of the patients sampled were not exposed to any significant risk of harm from interactions with conventional medicines, but it is not possible as yet to conclude that risks in general are over-estimated. The incidence of HDS use was also less than anticipated, and significantly less than reported in other areas, illustrating the problems when extrapolating results from one region (the UK), in one setting (NHS oncology) in where patterns of supplement use may be very different to those elsewhere.
Literature
1.
Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther. 2002;27:391–401.CrossRefPubMed
2.
Afifi FU, Wazaify M, Jabr M, Treish E. The use of herbal preparations as complementary and alternative medicine (CAM) in a sample of patients with cancer in Jordan. Complement Ther Clin Pract. 2010;16:208–12.CrossRefPubMed
3.
Alsanad SM, Williamson EM, Howard RL. Cancer patients at risk of herb/food supplement–drug interactions: a systematic review. Phytother Res. 2014;28:1749–55.CrossRefPubMed
4.
Champy P, Melot A, Guérineau Eng V, Gleye C, Fall D, Höglinger GU, Ruberg M, Lannuzel A, Laprévote O, Laurens A, Hocquemiller R. Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in Guadeloupe. Mov Disord. 2005;20:1629–33.CrossRefPubMed
5.
Chrystal K, Allan S, Forgeson G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional cancer treatment centre. NZ Med J. 2003;116:875–903.
6.
Cui Y, Shu XO, Gao Y, Wen W, Ruan ZX, Jin F, Zheng W. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Res Treat. 2004;85:263–70.CrossRefPubMed
7.
Ernst E. The current position of complementary/alternative medicine in cancer. Eur J Cancer. 2003;39:2273–7.CrossRefPubMed
8.
Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther. 2009;8:29–36.CrossRefPubMed
9.
10.
Goey A, Beijnen J, Schellens J. Herb–Drug Interactions in Oncology. Clin Pharmacol Ther. 2014;95:354–5.CrossRefPubMed
11.
Gratus C, Damery S, Wilson S, Warmington S, Routledge P, Grieve R, Steven N, Jones J, Greenfield S. The use of herbal medicines by people with cancer in the UK: a systematic review of the literature. QJM. 2009;102:831–42.CrossRefPubMed
12.
Heinrich M, Barnes J, Gibbons S, Williamson EM. Fundamentals of Pharmacognosy and Phytotherapy. 2012. Elsevier Health Sciences.
13.
Hermann R, von Richter O. Clinical evidence of herbal drugs as perpetrators of pharmacokinetic drug interactions. Planta Med. 2012;78(13):1458–77.CrossRefPubMed
14.
Hübner J. Complementary and alternative medicine in oncology. Versicherungsmedizin. 2013;65:79–83.PubMed
15.
Izzo AA. Interactions between herbs and conventional drugs: overview of the clinical data. Med Princ Pract. 2012;21:404–28.CrossRefPubMed
16.
Izzo AA, Kim SH, Radhakrishnan R, Williamson EM. A critical approach to evaluating clinical efficacy, adverse events and drug interactions of commonly used herbal remedies. Phytother Res. 2016;30:691–700.CrossRefPubMed
17.
18.
Lee AH, Ingraham SE, Kopp M, Foraida MI, Jazieh AR. The incidence of potential interactions between dietary supplements and prescription medications in cancer patients at a Veterans Administration Hospital. Am J Clin Oncol. 2006;29:178–82.CrossRefPubMed
19.
Mathijssen RH, Verweij J, DE Bruijn P, Loos WJ, Sparreboom A. Effects of St. John’s wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247–9.CrossRefPubMed
20.
McCune JS, Hatfield AJ, Blackburn AA, Leith PO, Livingston RB, Ellis GK. Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer. 2004;12:454–62.CrossRefPubMed
21.
Mclay J, Stewart D, George J, Rore C, Heys S. Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions? Eur J Clin Pharmacol. 2012;68:811–9.CrossRefPubMed
22.
Meijerman I, Beijnen JH, Schellens JH. Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist. 2006;11:742–52.CrossRefPubMed
23.
Molassiotis A, Panteli V, Patiraki E, Ozden G, Platin N, Madsen E, Browall M, Fernandez-Ortega P, Pud D, Margulies A. Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract. 2006;12:34–9.CrossRefPubMed
24.
Rotblatt M, Ziment I. Evidence-based herbal medicine. Philadelphia: Hanley & Belfus; 2002.
25.
Russo E, Scicchitano F, Whalley BJ, Mazzitello C, Ciriaco M, Esposito S, Patanè M, Upton R, Pugliese M, Chimirri S. Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug–drug interactions. Phytother Res. 2014;28:643–55.CrossRefPubMed
26.
Suchard JR, Wallace KL, Gerkin RD. Acute cyanide toxicity caused by apricot kernel ingestion. Ann Emerg Med. 1998;32:742–4.CrossRefPubMed
27.
Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John’s wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos. 2005;33:547–54.CrossRefPubMed
28.
Thomsen M, Schmidt M, Vitetta L, Sali A. Do herbs increase the risk of herb–drug interactions for patients with arthritis? Ann Rheumatic Dis. 2005;64:1527–28.
29.
Tuna S, Dizdar O, Calis M. The prevalence of usage of herbal medicines among cancer patients. System. 2011;83:32.
30.
Vickers KA, Jolly KB, Greenfield SM. Herbal medicine: women’s views, knowledge and interaction with doctors: a qualitative study. BMC Complement Altern Med. 2006;6:40.CrossRefPubMedPubMedCentral
31.
Werneke U, Earl J, Seydel C, Horn O, Crichton P, Fannon D. Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer. 2004;90:408–13.CrossRefPubMedPubMedCentral
32.
33.
Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf. 2005;4:355–78.CrossRefPubMed
34.
Williamson EM, Driver SB, Baxter K, Lee CR. Stockley’s Herbal Medicine’s Interactions: a guide to the interactions of herbal medicines. London: Pharmaceutical Press; 2013.
35.
Wold RS, Lopez ST, Yau CL, Butler LM, Pareo-Tubbeh SL, Waters DL, Garry PJ, Baumgartner RN. Increasing trends in elderly persons’ use of non-vitamin, non-mineral dietary supplements and concurrent use of medications. J Am Diet Assoc. 2005;105:54–63.CrossRefPubMed
36.
Zachariae R, Johannessen H. A methodological framework for evaluating the evidence for Complementary and Alternative Medicine (CAM) for cancer. Cancers. 2011;3:773–88.CrossRefPubMedPubMedCentral
37.
Zeller T, Muenstedt K, Stoll C, Schweder J, Senf B, Ruckhaeberle E, Becker S, Serve H, Huebner J. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin. 2013;139:357–65.CrossRef
Metadata
Title
An assessment of the impact of herb-drug combinations used by cancer patients
Authors
Saud M. Alsanad
Rachel L. Howard
Elizabeth M. Williamson
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-016-1372-x

Other articles of this Issue 1/2016

BMC Complementary Medicine and Therapies 1/2016 Go to the issue

Study protocol

Evaluating validity of various acupuncture device types: a random sequence clinical trial

Research article

Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Research article

Fraxinus xanthoxyloides leaves reduced the level of inflammatory mediators during in vitro and in vivo studies

Research article

α-glucosidase and glycation inhibitory effects of costus speciosus leaves

Research article

Fructus mume extracts alleviate cognitive impairments in 5XFAD transgenic mice

Research article

Identification of more objective biomarkers for Blood-Stasis syndrome diagnosis